In conclusion, CSF NfL can be used as a pathophysiological biomarker which reflects early neurodegeneration, and as a prognostic biomarker which reflects downstream neurodegenerative changes along the AD continuum. This evidence concerns the gene NEFL and Alzheimer disease.